P R O H O S T   O n l i n e The Newsletter of Biotechnology Insight and Investment
Eye on the News [ Home | Contents | Search | Next | Previous | Up ]

GENZYME TRANSGENICS: A STEP FORWARD .. PURIFICATION

bigcockteenaddiction xndx

Date: 12 Dec 2007
Time: 09:34:21

Comments

http://www.bigcockteenaddiction.com/?wm_login=topis http://www.bigcockteenaddiction.com/tour2/?wm_login=topis http://www.blinddatebangers.com/?wm_login=topis http://www.busstopwhores.com/?wm_login=topis http://www.castingcouchteens.com/?wm_login=topis http://www.coedsneedcash.com/?wm_login=topis http://www.collegeteensbookbang.com/?wm_login=topis http://www.milfhunter.com/?id=chikenn

Date: 25 Jun 2001
Time: 11:43:11

Comments

MONTREAL, June 22, 2001: At the International Recovery of Biological Products Conference held recently in Cancun (Mexico), Genzyme Transgenics (GZTC), in collaboration with ProMetic Life Sciences (ProMetic),presented data related to ton-scale manufacture of transgenic human serum albumin (tghSA).

Ton-scale recovery and purification is a daunting challenge due to the magnitude and scale of the process, and the increased need for high purity. By combining their technologies, GTC and ProMetic were able to develop the technology that would make this ton-scale process cost-effective while achieving the volume and purity required for this pharmaceutical product.

Under this partnership, ProMetic has provided its purification technology, in particular its albumin binding absorbents (ligands), to be incorporated into GTC's manufacturing process for tghSA produced from transgenic cows.

The current world market consumes approximately 450,000 kg of albumin annually representing over $US 1.5 billion in sales.

Albumin is an abundant protein found in plasma. It helps retain water in the system. It is frequently used for patients who are hypovolemic and have lost large amounts of blood or fluids. Through this collaboration, GTC and ProMetic hope to furnish the growing need for this pharmaceutical protein.

"This collaboration underscores GTC's confidence in our purification technology and speaks to the effectiveness and consistency for producing large- scale levels of biopharmaceuticals," said Mr. Pierre Laurin, Chairman and CEO of ProMetic. "We are especially proud that we were able to meet the low manufacturing cost and high purity requirements essential for the feasibility of ton-scale production." "This collaboration takes our long standing relationship with GTC one step further, together achieving a major technological feat that could set new precedents," he added.

The collaboration between Genzyme and ProMetic was established in May 1999.

ProMetic Life Sciences Inc. (TSE: PLI), with headquarters in Montreal, Quebec, and additional facilities in the UK, owns proprietary enabling technology essential for use in therapeutics, large-scale drug purification, chemical genomics and proteomics, drug delivery and drug development. This existing technology can dramatically lower costs, increase yield, and improve efficacy of existing and new bio-pharmaceutical products. ProMetic accomplishes this through strategic partnerships and in-house therapeutic development. Additional information is available on the company's website: http://www.prometic.com.

This press release contains forward-looking statements that involve risks and uncertainties, including, but not limited to the Company's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products and to obtain contracts for its products and services and commercial acceptance of advanced affinity separation technology. Shareholders are cautioned that these statements are predictions and these actual events or results may differ materially from those anticipated in these forward-looking statements.

Comments:

Grnzyme Transgenics is providing the solution for the bottleneck in manufacturing. The firm has moved from proving drug production feasibility, to attracting alliances, to providing the purest forms of the biological treatments - all in a cost effective package.

Prohost is an independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Send mail to CompanyWebmaster with questions or comments about this web site. Copyright © 2001 CompanyLongName